Literature DB >> 34757067

Deep Learning and Pathomics Analyses Reveal Cell Nuclei as Important Features for Mutation Prediction of BRAF-Mutated Melanomas.

Randie H Kim1, Sofia Nomikou2, Nicolas Coudray3, George Jour4, Zarmeena Dawood5, Runyu Hong6, Eduardo Esteva7, Theodore Sakellaropoulos8, Douglas Donnelly9, Una Moran5, Aristides Hatzimemos10, Jeffrey S Weber11, Narges Razavian12, Iannis Aifantis8, David Fenyo13, Matija Snuderl14, Richard Shapiro15, Russell S Berman15, Iman Osman1, Aristotelis Tsirigos16.   

Abstract

Image-based analysis as a method for mutation detection can be advantageous in settings when tumor tissue is limited or unavailable for direct testing. In this study, we utilize two distinct and complementary machine-learning methods of analyzing whole-slide images for predicting mutated BRAF. In the first method, whole-slide images of melanomas from 256 patients were used to train a deep convolutional neural network to develop a fully automated model that first selects for tumor-rich areas (area under the curve = 0.96) and then predicts for mutated BRAF (area under the curve = 0.71). Saliency mapping was performed and revealed that pixels corresponding to nuclei were the most relevant to network learning. In the second method, whole-slide images were analyzed using a pathomics pipeline that first annotates nuclei and then quantifies nuclear features, showing that mutated BRAF nuclei were significantly larger and rounder than BRAF‒wild-type nuclei. Finally, we developed a model that combines clinical information, deep learning, and pathomics that improves the predictive performance for mutated BRAF to an area under the curve of 0.89. Not only does this provide additional insights on how BRAF mutations affect tumor structural characteristics, but machine learning‒based analysis of whole-slide images also has the potential to be integrated into higher-order models for understanding tumor biology.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34757067      PMCID: PMC9054943          DOI: 10.1016/j.jid.2021.09.034

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   7.590


  24 in total

1.  Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.

Authors:  Alexander M Menzies; Lauren E Haydu; Lydia Visintin; Matteo S Carlino; Julie R Howle; John F Thompson; Richard F Kefford; Richard A Scolyer; Georgina V Long
Journal:  Clin Cancer Res       Date:  2012-04-24       Impact factor: 12.531

2.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

3.  Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis.

Authors:  Yu Fu; Alexander W Jung; Ramon Viñas Torne; Santiago Gonzalez; Harald Vöhringer; Artem Shmatko; Lucy R Yates; Mercedes Jimenez-Linan; Luiza Moore; Moritz Gerstung
Journal:  Nat Cancer       Date:  2020-07-27

4.  Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research.

Authors:  Lindsay G Wich; Heather K Hamilton; Richard L Shapiro; Anna Pavlick; Russell S Berman; David Polsky; Judith D Goldberg; Eva Hernando; Prashiela Manga; Michelle Krogsgaard; Hideko Kamino; Farbod Darvishian; Peng Lee; Seth J Orlow; Harry Ostrer; Nina Bhardwaj; Iman Osman
Journal:  Am J Transl Res       Date:  2009-01-01       Impact factor: 4.060

5.  The role of BRAF V600 mutation in melanoma.

Authors:  Paolo A Ascierto; John M Kirkwood; Jean-Jacques Grob; Ester Simeone; Antonio M Grimaldi; Michele Maio; Giuseppe Palmieri; Alessandro Testori; Francesco M Marincola; Nicola Mozzillo
Journal:  J Transl Med       Date:  2012-07-09       Impact factor: 5.531

6.  Predicting cancer outcomes from histology and genomics using convolutional networks.

Authors:  Pooya Mobadersany; Safoora Yousefi; Mohamed Amgad; David A Gutman; Jill S Barnholtz-Sloan; José E Velázquez Vega; Daniel J Brat; Lee A D Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-12       Impact factor: 11.205

7.  Methods for Segmentation and Classification of Digital Microscopy Tissue Images.

Authors:  Quoc Dang Vu; Simon Graham; Tahsin Kurc; Minh Nguyen Nhat To; Muhammad Shaban; Talha Qaiser; Navid Alemi Koohbanani; Syed Ali Khurram; Jayashree Kalpathy-Cramer; Tianhao Zhao; Rajarsi Gupta; Jin Tae Kwak; Nasir Rajpoot; Joel Saltz; Keyvan Farahani
Journal:  Front Bioeng Biotechnol       Date:  2019-04-02

8.  Virtual biopsy using MRI radiomics for prediction of BRAF status in melanoma brain metastasis.

Authors:  Ben Shofty; Moran Artzi; Shai Shtrozberg; Claudia Fanizzi; Francesco DiMeco; Oz Haim; Shira Peleg Hason; Zvi Ram; Dafna Ben Bashat; Rachel Grossman
Journal:  Sci Rep       Date:  2020-04-20       Impact factor: 4.379

9.  CellProfiler: image analysis software for identifying and quantifying cell phenotypes.

Authors:  Anne E Carpenter; Thouis R Jones; Michael R Lamprecht; Colin Clarke; In Han Kang; Ola Friman; David A Guertin; Joo Han Chang; Robert A Lindquist; Jason Moffat; Polina Golland; David M Sabatini
Journal:  Genome Biol       Date:  2006-10-31       Impact factor: 13.583

10.  Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features.

Authors:  Kun-Hsing Yu; Ce Zhang; Gerald J Berry; Russ B Altman; Christopher Ré; Daniel L Rubin; Michael Snyder
Journal:  Nat Commun       Date:  2016-08-16       Impact factor: 14.919

View more
  3 in total

Review 1.  Pediatric Sarcomas: The Next Generation of Molecular Studies.

Authors:  Petros Giannikopoulos; David M Parham
Journal:  Cancers (Basel)       Date:  2022-05-20       Impact factor: 6.575

2.  When blockchain meets artificial intelligence: An application to cancer histopathology.

Authors:  Runyu Hong; David Fenyö
Journal:  Cell Rep Med       Date:  2022-06-21

Review 3.  Computational pathology in ovarian cancer.

Authors:  Sandra Orsulic; Joshi John; Ann E Walts; Arkadiusz Gertych
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.